SEC Filings
Axogen Prostate Study Puts One-Sided Nerve Recovery At 80% Versus About 49% Historically
The small study uses historical comparisons, while hospital and patient surveys test a path to adoption before broad insurance coverage.
Axogen (AXGN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The small study uses historical comparisons, while hospital and patient surveys test a path to adoption before broad insurance coverage.
Deals
Axogen's $348 million cash pile at quarter-end was largely a bridge to a cash acquisition that closed October 1.
Earnings
Lindsey Hartley said the 2027 nerve tape figure is incremental, while 2026 guidance models an overlap she would not size.
Earnings
The company says about 80% of patients with six months of follow-up beat expected erectile recovery, and prostate sits outside its guidance.
Earnings
The nerve-repair company, now free of debt, also posted $350.1 million in cash and investments and closed its BioCircuit purchase.